These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 20943283)

  • 1. Association of ABCC2 polymorphisms with platinum-based chemotherapy response and severe toxicity in non-small cell lung cancer patients.
    Han B; Gao G; Wu W; Gao Z; Zhao X; Li L; Qiao R; Chen H; Wei Q; Wu J; Lu D
    Lung Cancer; 2011 May; 72(2):238-43. PubMed ID: 20943283
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel association between CD74 polymorphisms and hematologic toxicity in patients with NSCLC after platinum-based chemotherapy.
    Tan X; Wu Q; Cai Y; Zhao X; Wang S; Gao Z; Yang Y; Li X; Qian J; Wang J; Su B; Chen H; Han B; Jiang G; Lu D
    Clin Lung Cancer; 2014 Jan; 15(1):67-78.e12. PubMed ID: 24220096
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic Variants of the MDM2 Gene Are Predictive of Treatment-Related Toxicities and Overall Survival in Patients With Advanced NSCLC.
    Qian J; Liu H; Gu S; Wu Q; Zhao X; Wu W; Wang H; Wang J; Chen H; Zhang W; Wei Q; Jin L; Lu D
    Clin Lung Cancer; 2015 Sep; 16(5):e37-53. PubMed ID: 25818095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Associations of genetic polymorphisms of the transporters organic cation transporter 2 (OCT2), multidrug and toxin extrusion 1 (MATE1), and ATP-binding cassette subfamily C member 2 (ABCC2) with platinum-based chemotherapy response and toxicity in non-small cell lung cancer patients.
    Qian CY; Zheng Y; Wang Y; Chen J; Liu JY; Zhou HH; Yin JY; Liu ZQ
    Chin J Cancer; 2016 Sep; 35(1):85. PubMed ID: 27590272
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ABCC2 polymorphisms and survival in the Princess Margaret cohort study and the NCIC clinical trials group BR.24 trial of platinum-treated advanced stage non-small cell lung cancer patients.
    Cuffe S; Azad AK; Qiu X; Qiu X; Brhane Y; Kuang Q; Marsh S; Savas S; Chen Z; Cheng D; Leighl NB; Goss G; Laurie SA; Seymour L; Bradbury PA; Shepherd FA; Tsao MS; Chen BE; Xu W; Liu G
    Cancer Epidemiol; 2016 Apr; 41():50-6. PubMed ID: 26816351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polymorphisms in the base excision repair pathway modulate prognosis of platinum-based chemotherapy in advanced non-small cell lung cancer.
    Zhao W; Hu L; Xu J; Shen H; Hu Z; Ma H; Shu Y; Shao Y; Yin Y
    Cancer Chemother Pharmacol; 2013 May; 71(5):1287-95. PubMed ID: 23479135
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of polymorphisms in the XRCC1, XRCC3, and XPG genes on clinical outcomes of platinum-based chemotherapy for treatment of non-small cell lung cancer.
    Jin ZY; Zhao XT; Zhang LN; Wang Y; Yue WT; Xu SF
    Genet Mol Res; 2014 Mar; 13(3):7617-25. PubMed ID: 24737519
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The association between COX-2 polymorphisms and hematologic toxicity in patients with advanced non-small-cell lung cancer treated with platinum-based chemotherapy.
    Zhou F; Gao G; Ren S; Li X; He Y; Zhou C
    PLoS One; 2013; 8(4):e61585. PubMed ID: 23620771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediction models for platinum-based chemotherapy response and toxicity in advanced NSCLC patients.
    Yin JY; Li X; Li XP; Xiao L; Zheng W; Chen J; Mao CX; Fang C; Cui JJ; Guo CX; Zhang W; Gao Y; Zhang CF; Chen ZH; Zhou H; Zhou HH; Liu ZQ
    Cancer Lett; 2016 Jul; 377(1):65-73. PubMed ID: 27126360
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of XPD polymorphisms with severe toxicity in non-small cell lung cancer patients in a Chinese population.
    Wu W; Zhang W; Qiao R; Chen D; Wang H; Wang Y; Zhang S; Gao G; Gu A; Shen J; Qian J; Fan W; Jin L; Han B; Lu D
    Clin Cancer Res; 2009 Jun; 15(11):3889-95. PubMed ID: 19458053
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical significance of ERCC2 haplotype-tagging single nucleotide polymorphisms in patients with unresectable non-small cell lung cancer treated with first-line platinum-based chemotherapy.
    Kim SH; Lee GW; Lee MJ; Cho YJ; Jeong YY; Kim HC; Lee JD; Hwang YS; Kim IS; Lee S; Oh SY
    Lung Cancer; 2012 Sep; 77(3):578-84. PubMed ID: 22608006
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of ERCC1-C118T and -C8092A polymorphisms with lung cancer risk and survival of advanced-stage non-small cell lung cancer patients receiving platinum-based chemotherapy: a pooled analysis based on 39 reports.
    Xu TP; Shen H; Liu LX; Shu YQ
    Gene; 2013 Sep; 526(2):265-74. PubMed ID: 23727606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Polymorphisms in nucleotide excision repair genes XPC and XPD and clinical responses to platinum-based chemotherapy in advanced non-small cell lung cancer].
    Yuan P; Miao XP; Zhang XM; Wang ZH; Tan W; Sun Y; Xu BH; Lin DX
    Zhonghua Yi Xue Za Zhi; 2005 Apr; 85(14):972-5. PubMed ID: 16061005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. XPC Lys939Gln polymorphism is associated with the decreased response to platinum based chemotherapy in advanced non-small-cell lung cancer.
    Zhu XL; Sun XC; Chen BA; Sun N; Cheng HY; Li F; Zhang HM; Feng JF; Qin SK; Cheng L; Lu ZH
    Chin Med J (Engl); 2010 Dec; 123(23):3427-32. PubMed ID: 22166526
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Survival rates and tolerability of platinum-based chemotherapy regimens for elderly patients with non-small-cell lung cancer (NSCLC).
    Costa GJ; Fernandes AL; Pereira JR; Curtis JR; Santoro IL
    Lung Cancer; 2006 Aug; 53(2):171-6. PubMed ID: 16757059
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Li YQ; Zhang XY; Chen J; Yin JY; Li XP
    J Cancer Res Ther; 2018; 14(4):881-886. PubMed ID: 29970670
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The relationship between polymorphisms of genes regulating DNA repair or cell division and the toxicity of platinum and vinorelbine chemotherapy in advanced NSCLC patients.
    Powrózek T; Mlak R; Krawczyk P; Homa I; Ciesielka M; Kozioł P; Prendecka M; Milanowski J; Małecka-Massalska T
    Clin Transl Oncol; 2016 Feb; 18(2):125-31. PubMed ID: 26193985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacogenetic predictors of toxicity to platinum based chemotherapy in non-small cell lung cancer patients.
    Pérez-Ramírez C; Cañadas-Garre M; Alnatsha A; Villar E; Delgado JR; Faus-Dáder MJ; Calleja-Hernández MŸ
    Pharmacol Res; 2016 Sep; 111():877-884. PubMed ID: 27498158
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyclin D1 (CCND1) A870G gene polymorphism modulates smoking-induced lung cancer risk and response to platinum-based chemotherapy in non-small cell lung cancer (NSCLC) patients.
    Gautschi O; Hugli B; Ziegler A; Bigosch C; Bowers NL; Ratschiller D; Jermann M; Stahel RA; Heighway J; Betticher DC
    Lung Cancer; 2006 Mar; 51(3):303-11. PubMed ID: 16406195
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polymorphisms of p53 and MDM2 genes are associated with severe toxicities in patients with non-small cell lung cancer.
    Zheng D; Chen Y; Gao C; Wei Y; Cao G; Lu N; Hou Y; Jiang X; Wang J
    Cancer Biol Ther; 2014; 15(11):1542-51. PubMed ID: 25482940
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.